VivoSeq
Other

Sugammadex

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Sugammadex is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

35

clinical trials

Completed32 · 91%
Not yet recruiting2 · 6%
Enrolling by invitation1 · 3%

Clinical Trials

Trial Activity

35 trials

Sugammadex Dose Finding Under Two Years Old
Not yet recruiting·—·Phase 2·NCT06575036·33 enrolled
A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old
Not yet recruiting·UUniversity Hospital, Caen·Phase 4·NCT07477132·99 enrolled
Placental Transfer of Sugammadex in the Human Placental Perfusion Model
Enrolling by invitation·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT06634355·16 enrolled
The Influence Factors of Bispectral Index Values Increment Caused by Sugammadex
Completed·—·N/A·NCT06561633·135 enrolled
Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00535496·91 enrolled
Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency
Completed·UUniversity of South Florida·Phase 4·NCT02860507·50 enrolled
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00379613·45 enrolled
Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00421148·94 enrolled
Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)
Completed·UUniversity of California, San Francisco·Phase 2·NCT03532178·44 enrolled
Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal
Completed·HHospital Sultanah Aminah Johor Bahru·Phase 4·NCT01539044·49 enrolled
Sugammadex as Rescue Therapy
Completed·EEmory University·Phase 4·NCT05661409·46 enrolled
Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children
Completed·SSeoul National University Hospital·Phase 2·NCT03943888·40 enrolled
Sugammadex and Decreased Time to Extubation
Completed·YYale University·Phase 4·NCT03196167·90 enrolled
Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery
Completed·TTechnical University of Munich·Phase 4·NCT01101139·300 enrolled
A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00552929·102 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)